Target type: biologicalprocess
The series of events in which an (non-living) abiotic stimulus is received by a cell and converted into a molecular signal. [GOC:hb]
Abiotic stimuli, such as changes in temperature, light, water availability, pH, salinity, and nutrient levels, are critical environmental cues that organisms must detect and respond to for survival. The detection of abiotic stimuli involves a complex interplay of sensory receptors, signaling pathways, and gene regulatory networks. Here's a detailed breakdown of the process:
**1. Sensory Receptors:**
* **Specialized Proteins:** Organisms possess specialized proteins that act as sensory receptors, capable of sensing specific abiotic changes. These receptors can be located on the cell surface, within the cytoplasm, or within specific organelles.
* **Physical and Chemical Changes:** These receptors detect physical changes like temperature fluctuations (thermoreceptors) or light intensity (photoreceptors). Others sense chemical changes like variations in pH (chemoreceptors), salinity (osmoreceptors), or nutrient levels (nutrient receptors).
* **Signal Transduction:** Upon detection of the abiotic stimulus, these receptors undergo conformational changes, initiating a signal transduction cascade.
**2. Signal Transduction Pathways:**
* **Signal Amplification:** The initial signal from the receptor is often amplified through a series of protein interactions and modifications within the cell. This amplification ensures a robust response to even small changes in the environment.
* **Second Messengers:** Several signaling pathways involve the generation of second messengers like cyclic AMP (cAMP), calcium ions (Ca2+), or inositol triphosphate (IP3). These messengers further amplify and transmit the signal.
* **Protein Kinases and Phosphatases:** Key players in signal transduction are protein kinases, which add phosphate groups to proteins, and phosphatases, which remove phosphate groups. These modifications alter protein activity, directing the flow of information within the cell.
**3. Gene Regulation:**
* **Transcription Factors:** The signal eventually reaches the nucleus where it interacts with transcription factors. These proteins bind to specific DNA sequences, controlling the expression of genes involved in the organism's response to the stimulus.
* **Gene Expression:** The activation or repression of specific genes leads to the synthesis of proteins involved in the organism's adaptation. These proteins can be enzymes that catalyze metabolic reactions, structural proteins that alter cell shape, or signaling proteins that further modify the response.
**4. Physiological Responses:**
* **Cellular Level:** The changes in gene expression lead to various cellular responses, including changes in metabolism, ion transport, and cellular growth.
* **Organismal Level:** At the organismal level, these responses can manifest as behaviors like movement, changes in growth patterns, or adjustments in physiological processes like photosynthesis, respiration, or water uptake.
**Examples:**
* **Plants:** Plants detect changes in light intensity and direction through photoreceptors, triggering growth responses like phototropism (bending towards light) and photomorphogenesis (developmental changes in response to light).
* **Animals:** Animals use thermoreceptors to detect temperature fluctuations, triggering physiological adjustments like shivering, sweating, or changes in blood flow to maintain body temperature.
**Conclusion:**
The detection of abiotic stimuli is a crucial process for survival and adaptation. This complex and finely tuned system ensures that organisms can sense and respond to environmental changes, maximizing their chances of survival and reproduction in a constantly changing world.'
"
Protein | Definition | Taxonomy |
---|---|---|
Neuropeptide FF receptor 2 | A neuropeptide FF receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9Y5X5] | Homo sapiens (human) |
Substance-P receptor | A substance-P receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25103] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
astemizole | astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects. | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
econazole | 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. Econazole: An imidazole derivative that is commonly used as a topical antifungal agent. | dichlorobenzene; ether; imidazoles; monochlorobenzenes | |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
paroxetine | paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression. | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor |
phenylalanylphenylalanylamide | |||
cp 96345 | CP 96345: structure given in first source; potent nonpeptide antagonist of the substance P (NK1) receptor; CP 96344 is enantiomer of CP 96345 | ||
sr 48968 | SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968 | ||
7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one | 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one: structure given in first source; RP 68651 is the inactive (3aS,7aS)-isomer; substance P antagonist | ||
senktide | |||
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine | (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine: structure given in first source | ||
l 703606 | L 703606: structure given in first source | ||
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist | ||
l 733060 | 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source | piperidines | |
win 64821 | WIN 64821: a dimerized Trp-Phe condensate; structurally similar to verticillins and chaetocins; a nonpeptide neurokinin antagonist; structure given in first source; substance P antagonist | ||
substance p, pro(9)- | substance P, Pro(9)-: RN given refers to the (L-Pro)-isomer; RN for cpd without isomeric designation not available 3/91 | ||
substance p, sar(9)-met(o2)(11)- | substance P, Sar(9)-Met(O2)(11)-: a neurokinin-1 receptor agonist | ||
ranatachykinin a | ranatachykinin A: a tachykinin in frog (Rana catesbeiana) brain and intestine | ||
sr 142806 | |||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
bibp 3226 | BIBP 3226: a selective non-peptide neuropeptide Y Y1 receptor antagonist; structure given in first source; BIBP-3435 is the S-enantiomer | ||
cp 99994 | 3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer | ||
neurokinin a | Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI. | ||
neurokinin b | Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS. | polypeptide | |
sb 223412 | SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source | ||
seglitide | seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist | ||
biphalin | biphalin: enkephalin dimer; two fragments of Ala(2)-enkephalin are connected by a diamine bridge to form above cpd; structure given in first source | ||
netupitant | netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. netupitant: orally active neurokinin-1 receptor antagonist | aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes | antiemetic; neurokinin-1 receptor antagonist |
sb 222200 | quinolines | ||
sb 218795 | SB 218795: structure in first source | quinolines | |
substance p (6-11), tyr(6)-d-phe(7)-d-his(9)- | substance P (6-11), Tyr(6)-D-Phe(7)-D-His(9)-: substance P antagonist | ||
vofopitant | |||
pd 154075 | PD 154075: a non-peptide tachykinin NK1 receptor antagonist; structure given in first source | ||
edotecarin | |||
(2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine | (2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine: structure given in first source | ||
vestipitant | |||
ly 306740 | LY 306740: LY-307679 is the inactive enantiomer | ||
sdz nkt 343 | SDZ NKT 343: structure in first source | ||
orvepitant | |||
zd 6021 | ZD 6021: structure in first source | ||
phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide | |||
tak 637 | TAK 637: structure in first source | ||
casopitant | piperidines | ||
nkp 608 | |||
dnk 333 | DNK 333: a dual neurokinin NK1/NK2 receptor antagonist; structure in first source | ||
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
fmrfamide | FMRFamide: A molluscan neuroactive peptide which induces a fast excitatory depolarizing response due to direct activation of amiloride-sensitive SODIUM CHANNELS. (From Nature 1995; 378(6558): 730-3) | ||
rolapitant | azaspiro compound; ether; organofluorine compound; piperidines; pyrrolidin-2-ones | antiemetic; neurokinin-1 receptor antagonist | |
spiroquinazoline | spiroquinazoline: isolated from the fungus Aspergillus flavipes; structure given in first source; substance P antagonist | ||
ditryptophenaline | ditryptophenaline: structure in first source | ||
serlopitant | |||
kisspeptin-10 protein, human | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
RF9 | dipeptide | kisspeptin receptor agonist; neuropeptide FF receptor agonist; neuropeptide FF receptor antagonist | |
aprepitant | aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist |
l 742694 | L 742694: a neurokinin-1 receptor antagonist; structure given in first source |